GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Additional Paid-In Capital

CG Oncology (CG Oncology) Additional Paid-In Capital : $715.81 Mil(As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Additional Paid-In Capital?


CG Oncology's quarterly additional paid-in capital increased from Sep. 2023 ($5.80 Mil) to Dec. 2023 ($6.84 Mil) and increased from Dec. 2023 ($6.84 Mil) to Mar. 2024 ($715.81 Mil).

CG Oncology's annual additional paid-in capital increased from Dec. 2021 ($3.27 Mil) to Dec. 2022 ($3.64 Mil) and increased from Dec. 2022 ($3.64 Mil) to Dec. 2023 ($6.84 Mil).

CG Oncology Additional Paid-In Capital Historical Data

The historical data trend for CG Oncology's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Additional Paid-In Capital Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Additional Paid-In Capital
3.27 3.64 6.84

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial 3.64 - 5.80 6.84 715.81

CG Oncology Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

CG Oncology Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of CG Oncology's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Additional Paid-In Capital
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024